• Ashleigh Witt, Jo A Douglass, and Nur-Shirin Harun.
• Department of Respiratory Medicine, The Royal Melbourne Hospital, Melbourne, Victoria, Australia.
• Intern Med J. 2022 Sep 1; 52 (9): 1478-1487.

AbstractAsthma is a common but complex heterogenous inflammatory airway disorder. Despite significant developments in our understanding of the pathophysiology and treatment of asthma, it remains a major cause of mortality and morbidity. Optimal management involves addressing modifiable risk factors, titration of inhaled pharmacotherapy in a stepwise approach and, in severe disease, consideration of biologic agents. Appreciation of the clinical characteristics of asthma and recognition of the immune pathways involved has allowed the development of phenotypic and endotypic subtypes of asthma to be better defined. This has revolutionised asthma management, allowing risk stratification of patients, targeted use of biologic agents to modify cytokine responses that drive asthma and improved patient outcomes. Patient education and engagement are critical to the management of this disease in an era of personalised medicine and a rapidly changing global environment.© 2022 Royal Australasian College of Physicians.

9 keywords...

hide…